In contrast to common therapies aiming at reducing brain Aβ load, increasing DR6 specifically in the vasculature, can bolster the resilience of BECs at the BBB against the detrimental impact of Aβ and other pathological factors linked to AD. This evidence concerns the gene TNFRSF21 and Alzheimer disease.